DCTH Long Call Strategy

DCTH (Delcath Systems, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

DCTH (Delcath Systems, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $400.8M, a trailing P/E of 745.47, a beta of 0.54 versus the broader market, a 52-week range of 8.12-18.23, average daily share volume of 449K, a public-listing history dating back to 2018, approximately 96 full-time employees. These structural characteristics shape how DCTH stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.54 indicates DCTH has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 745.47 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a long call on DCTH?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current DCTH snapshot

As of May 15, 2026, spot at $11.11, ATM IV 65.80%, IV rank 10.33%, expected move 18.86%. The long call on DCTH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on DCTH specifically: DCTH IV at 65.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a DCTH long call, with a market-implied 1-standard-deviation move of approximately 18.86% (roughly $2.10 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DCTH expiries trade a higher absolute premium for lower per-day decay. Position sizing on DCTH should anchor to the underlying notional of $11.11 per share and to the trader's directional view on DCTH stock.

DCTH long call setup

The DCTH long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DCTH near $11.11, the first option leg uses a $11.11 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DCTH chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DCTH shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$11.11N/A

DCTH long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

DCTH long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on DCTH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on DCTH

Long calls on DCTH express a bullish thesis with defined risk; traders use them ahead of DCTH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

DCTH thesis for this long call

The market-implied 1-standard-deviation range for DCTH extends from approximately $9.01 on the downside to $13.21 on the upside. A DCTH long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current DCTH IV rank near 10.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DCTH at 65.80%. As a Healthcare name, DCTH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DCTH-specific events.

DCTH long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DCTH positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DCTH alongside the broader basket even when DCTH-specific fundamentals are unchanged. Long-premium structures like a long call on DCTH are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DCTH chain quotes before placing a trade.

Frequently asked questions

What is a long call on DCTH?
A long call on DCTH is the long call strategy applied to DCTH (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With DCTH stock trading near $11.11, the strikes shown on this page are snapped to the nearest listed DCTH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are DCTH long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the DCTH long call priced from the end-of-day chain at a 30-day expiry (ATM IV 65.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a DCTH long call?
The breakeven for the DCTH long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DCTH market-implied 1-standard-deviation expected move is approximately 18.86%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on DCTH?
Long calls on DCTH express a bullish thesis with defined risk; traders use them ahead of DCTH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current DCTH implied volatility affect this long call?
DCTH ATM IV is at 65.80% with IV rank near 10.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related DCTH analysis